Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT01870505
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT01857193
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Massachusetts General Hospital Onc Dept, Boston, Massachusetts, United States
🇺🇸Oregon Health and Science University SC-5, Portland, Oregon, United States
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 36
- Registration Number
- NCT01831076
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01814397
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 309
- Registration Number
- NCT01783444
- Locations
- 🇺🇸
University of California at Los Angeles Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸Sharp Memorial Hospital SharpClinicalOncologyResearch, San Diego, California, United States
🇺🇸Oncology Hematology Care Inc Oncology Hematology Care 2, Cincinnati, Ohio, United States
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT01743560
- Locations
- 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT01720602
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT01698918
- Locations
- 🇺🇸
Breastlink Medical Group Dept. of BreastlinkResearchGrp, Long Beach, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Alabama Comprehensive Cancer Center SC-2, Birmingham, Alabama, United States
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1939
- Registration Number
- NCT01674140
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Aria Health-Torresdale Campus, Philadelphia, Pennsylvania, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01664754
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.